Long-term follow-up of the NI006-101 trial shows that cliramitug, a monoclonal antibody targeting misfolded transthyretin, sustains clinical benefit in cardiac amyloidosis over 29.3 months, with continued amyloid reduction and functional improvement. — Photo by www.kaboompics.com on Pexels (Pexels License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
